



Caldesmon (phospho Ser789) Polyclonal Antibody


Catalog No	YP-Ab-03051
Isotype	IgG
Reactivity	Human;Mouse;Rat
Applications	WB;IHC;IF;ELISA
Gene Name	CALD1
Immunogen	The antiserum was produced against synthesized peptide derived from human Caldesmon around the phosphorylation site of Ser789. AA range:744-793
Specificity	Phospho-Caldesmon (S789) Polyclonal Antibody detects endogenous levels of Caldesmon protein only when phosphorylated at S789.
Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source	Polyclonal, Rabbit,IgG
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Dilution	Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications.
Concentration	1 mg/ml
Purity	≥90%
Storage Stability	-20°C/1 year
Synonyms	CAD;CALD 1;CALD1;CALD1_HUMAN;Caldesmon 1;Caldesmon 1 Isoform 1; Caldesmon 1 Isoform 2;Caldesmon 1 Isoform 3;Caldesmon 1 Isoform 4; Caldesmon 1 Isoform 5;Caldesmon;Caldesmon1;CDM;H CAD;HCAD;L CAD; LCAD;MGC21352;NAG22
Observed Band	80kD
Calculated Molecular Weight	80kD
Cell Pathway	Cytoplasm, cytoskeleton . Cytoplasm, myofibril . Cytoplasm, cytoskeleton, stress fiber . On thin filaments in smooth muscle and on stress fibers in fibroblasts (nonmuscle). .
Tissue Specificity	High-molecular-weight caldesmon (isoform 1) is predominantly expressed in smooth muscles, whereas low-molecular-weight caldesmon (isoforms 2, 3, 4 and 5) are widely distributed in non-muscle tissues and cells. Not expressed in skeletal muscle or heart.




Function	domain: The N-terminal part seems to be a myosin/calmodulin-binding domain, and the C-terminal a tropomyosin/actin/calmodulin-binding domain. These two domains are separated by a central helical region in the smooth-muscle form., function: Actin- and myosin-binding protein implicated in the regulation of actomyosin interactions in smooth muscle and nonmuscle cells (could act as a bridge between myosin and actin filaments). Stimulates actin binding of tropomyosin which increases the stabilization of actin filament structure. In muscle tissues, inhibits the actomyosin ATPase by binding to F-actin. This inhibition is attenuated by calcium-calmodulin and is potentiated by tropomyosin. Interacts with actin, myosin, two molecules of tropomyosin and with calmodulin. Also play an essential role during cellular mitosis and receptor capping., PTM: In non-muscle cells, phosphorylation by CDC2 during mit
Background	This gene encodes a calmodulin- and actin-binding protein that plays an essential role in the regulation of smooth muscle and nonmuscle contraction. The conserved domain of this protein possesses the binding activities to Ca(2+)-calmodulin, actin, tropomyosin, myosin, and phospholipids. This protein is a potent inhibitor of the actin-tropomyosin activated myosin MgATPase, and serves as a mediating factor for Ca(2+)-dependent inhibition of smooth muscle contraction. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.




Products Images




Western Blot analysis of various cells using
Phospho-Caldesmon (S789) Polyclonal Antibody



Western Blot analysis of 293 cells using
Phospho-Caldesmon (S789) Polyclonal Antibody




Immunofluorescence analysis of HeLa cells, using
Caldesmon (Phospho-Ser789) Antibody. The picture
on the right is blocked with the phospho peptide.



Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using Caldesmon (Phospho-Ser789) Antibody. The picture on the right is blocked with the phospho peptide.

CALDESMON
(pSer789)



Western blot analysis of lysates from HeLa cells treated with EGF 200ng/ml 30', using Caldesmon (Phospho-Ser789) Antibody. The lane on the right is blocked with the phospho peptide.